Testosterone

Testosterone

SCHEMBL547899

CC(=O)O.C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O

nearest known ligand 0.91

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AR

The experimentally established mechanism targets of Testosterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR known ✓ P10275 4/20 0.91
LMNA P02545 6/20 0.91
CYP3A4 P08684 6/20 0.91
SHBG P04278 6/20 0.91
MAPT P10636 5/20 0.91
HSD17B10 Q99714 4/20 0.91
TSHR P16473 4/20 0.91
SERPINA6 P08185 4/20 0.91
CYP19A1 P11511 4/20 0.91
MAPK1 P28482 4/20 0.91
NR3C1 P04150 3/20 0.91
PGR P06401 3/20 0.91
GPBAR1 Q8TDU6 3/20 0.91
SIGMAR1 Q99720 3/20 0.91
SNCA P37840 2/20 0.91
CACNA1C Q13936 2/20 0.91
CYP51A1 Q16850 2/20 0.91
OR51E2 Q9H255 1/20 0.91
SMN1; SMN2 Q16637 5/20 0.73
ALDH1A1 P00352 4/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Testosterone SCHEMBL8814300 0.96 LMNA (0.93) LMNACYP3A4SHBGMAPTHSD17B10
Testosterone SCHEMBL4602538 0.95 AR (1.00) LMNACYP3A4SHBGMAPTHSD17B10
Epitestosterone SCHEMBL16305625 0.95 AR (1.00) LMNACYP3A4SHBGMAPTHSD17B10
Epitestosterone SCHEMBL14034478 0.95 AR (1.00) LMNACYP3A4SHBGMAPTHSD17B10
Epitestosterone SCHEMBL13752937 0.95 AR (1.00) LMNACYP3A4SHBGMAPTHSD17B10
Epitestosterone SCHEMBL617693 0.95 AR (1.00) LMNACYP3A4SHBGMAPTHSD17B10
Epitestosterone SCHEMBL12367194 0.95 AR (1.00) LMNACYP3A4SHBGMAPTHSD17B10
Epitestosterone SCHEMBL22704809 0.95 AR (1.00) LMNACYP3A4SHBGMAPTHSD17B10
Epitestosterone SCHEMBL21957465 0.95 AR (1.00) LMNACYP3A4SHBGMAPTHSD17B10
Epitestosterone SCHEMBL11588466 0.95 AR (1.00) LMNACYP3A4SHBGMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 431 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122063219-A Method for simultaneously measuring 31 stimulant substances in complex matrix cosmetics 国家体育总局反兴奋剂中心(中国反兴奋剂中心) 2026-05-19 CN claimed
CN-119165068-A Construction of lymphoma early diagnosis model based on peripheral blood metabonomics by utilizing neural network and application 中国医科大学附属盛京医院 2024-12-20 CN claimed
CN-118108782-A Preparation method of mesotrione intermediate 潘高峰 2024-05-31 CN claimed
CN-110618225-B Method for constructing database to detect hormone 吉林出入境检验检疫局检验检疫技术中心 2021-11-26 CN claimed
CN-108796021-B Engineering bacterium and application thereof in preparing testosterone 沈阳博泰生物制药有限公司 2021-03-19 CN claimed
CN-110618225-A Method for constructing database to detect hormone 吉林出入境检验检疫局检验检疫技术中心 2019-12-27 CN claimed
US-9827407-B2 Applicator system for applying a viscous liquid to the human skin FERRING B.V. (NL) 2017-11-28 US claimed
US-9616072-B2 Reduction of side effects from aromatase inhibitors used for treating breast cancer CHAVAH PTY LTD. (AU) 2017-04-11 US claimed
US-9452174-B2 Oral transmucosal pharmaceutical compositions including testosterone and a C-SERM PROFESSIONAL COMPOUNDING CENTERS OF AMERICA (US) 2016-09-27 US claimed
US-20160129015-A1 Reduction of Side Effects from Aromatase Inhibitors Used for Treating Breast Cancer Havah Therapeutics Pty Ltd. (AU) 2016-05-12 US claimed
US-20030153540-A1 Administration of non-oral androgenic steroids to women ALLERGAN SALES, LLC 2003-08-14 US claimed
US-6593313-B2 Administering to the vagina, vulvar area or urethra of the female a pharmaceutical formulation comprises a vasoactive agent selected from natural or synthetic prostaglandins, endothelial derived relaxation factors, hypotensive agents VIVUS, INC. 2003-07-15 US claimed
US-6583129-B1 Administering testosterone and estrogen derivatives to improve health in humans having elevated sex hormone binding globulins; hormone replacement therapy WATSON PHARMACEUTICALS, INC. 2003-06-24 US claimed
US-20030062042-A1 Aerosol generating method and device ALEXZA PHARMACEUTICALS, INC. 2003-04-03 US claimed
US-20030051728-A1 Method and device for delivering a physiologically active compound ALEXZA PHARMACEUTICALS, INC. 2003-03-20 US claimed
US-6469016-B1 VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION VIVUS, INC. 2002-10-22 US claimed
EP-1189619-A1 ADMINISTRATION OF NON-ORAL ANDROGENIC STEROIDS TO WOMEN Watson Pharmaceuticals, Inc. (US) 2002-03-27 EP claimed
WO-2000076522-A1 ADMINISTRATION OF NON-ORAL ANDROGENIC STEROIDS TO WOMEN WATSON PHARMACEUTICALS, INC. (US) 2000-12-21 WO claimed
US-6099864-A In situ activation of microcapsules THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (US) 2000-08-08 US claimed
WO-1999059554-A1 IN SITU ACTIVATION OF MICROCAPSULES NASA/JOHNSON SPACE CENTER (US) 1999-11-25 WO claimed